GleamWall
中文EN

MDLN Medline Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 2046386 · Fiscal year ends 12/31

Financial factors as of 2026-09-26 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin25.7%
Operating margin5.7%
Net margin1.9%
FCF margin6.2%
EBITDA margin9.0%

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets51.7%
Debt / equity1.07x
Current ratio4.04x
Interest coverage2.50x

Cash quality & payout

Operating cash flow / net income4.13x
Accruals ratio—
Payout ratio—
Capex / revenue1.6%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY2025*2025-12-16
Income statement
Revenue$28.43B—
Cost of revenue$20.91B—
Gross profit$7.52B—
R&D expense$80.00M—
SG&A expense$4.52B—
Operating income$2.21B—
Interest expense$945.00M—
Pretax income$1.25B—
Income tax$91.00M—
Net income$1.16B$1.15B
EBITDA$3.22B—
EPS (basic)-0.01—
EPS (diluted)-0.01—
Weighted avg. shares (diluted)810.00M—
Balance sheet
Cash & equivalents$1.94B—
Short-term investments$0—
Receivables$3.53B—
Inventory$4.77B—
Current assets$10.68B—
PP&E, net$4.78B—
Goodwill$8.08B—
Intangibles$13.89B—
Total assets$38.48B—
Current liabilities$2.49B—
Short-term debt$77.00M—
Long-term debt$12.48B—
Total debt$12.56B—
Total liabilities$19.20B—
Shareholders' equity$10.74B—
Net debt$10.62B—
Cash flow statement
Operating cash flow$1.74B—
Capital expenditure$447.00M—
Free cash flow$1.30B—
Investing cash flow-$474.00M—
Financing cash flow$399.00M—
Depreciation & amortization$1.01B—
Stock-based compensation$76.00M—
Share buybacks$33.00M—

Free plan shows the latest 2 periods; Pro shows all 4 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.